Amendments to the Claims:

1. (original) An isolated polypeptide comprising a sequence selected from:
   (i) the amino acid sequence of SEQ ID NO: 2;
   (ii) an allelic or species variant of a sequence of (i);
   (iii) a variant of a sequence of (i) having at least 60% identity over the full length of SEQ ID NO: 2 and having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or
   (iv) a fragment of (i) or (ii) which does not have the amino acid sequence of SEQ ID NO: 4, an allelic or species variant of the sequence of SEQ ID NO: 4 or a fragment thereof and which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.

2. (currently amended) A variant or fragment of the polypeptide defined by the amino acid sequence set forth in SEQ. ID. No. 2 suitable for raising specific antibodies for said polypeptide and/or ~~an allelic or species~~ a naturally occurring variant thereof.

3. (currently amended) A polynucleotide encoding a polypeptide as claimed in claim 1 [[or 2]].

4. (original) A polynucleotide as claimed in claim 3 which is a cDNA.

5. (original) A polynucleotide encoding a polypeptide as claimed in claim 1, which polynucleotide comprises:
   (a) the nucleic acid sequence of SEQ ID NO: 1 or the coding sequence thereof and/or a sequence complementary thereto;
   (b) a sequence which hybridises to a sequence as defined in (a);
   (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or

(d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

6. (currently amended) An expression vector comprising a polynucleotide sequence as claimed in ~~any one of claims 3 to 5~~ claim 3, which is capable of expressing a polypeptide ~~according to claim 1 or 2~~ comprising a sequence selected from:

(j) the amino acid sequence of SEQ ID NO: 2;

(ii) an allelic or species variant of a sequence of (i);

(iii) a variant of a sequence of (i) having at least 60% identity over the full length of SEQ ID NO: 2 and having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or

(iv) a fragment of (i) or (ii) which does not have the amino acid sequence of SEQ ID NO: 4, an allelic or species variant of the sequence of SEQ ID NO: 4 or a fragment thereof and which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.

7. (original) A host cell containing an expression vector according to claim 6.

8. (currently amended) An antibody specific for a polypeptide as claimed in claim 1 ~~or claim 2~~.

9. (original) An isolated polynucleotide which directs expression *in vivo* of a polypeptide as claimed in claim 1.

10. [cancelled]

11. (currently amended) A pharmaceutical composition comprising a polypeptide as claimed in claim 1 ~~or a polynucleotide as claimed in claim 9~~ and a pharmaceutically acceptable carrier or diluent.

12. [cancelled]

13. (currently amended) A method of treating a patient having a Type 1 interferon treatable disease, which comprises administering to said patient an effective amount of a polypeptide as claimed in claim 1 ~~or a polynucleotide as claimed in claim 9~~.

14. (currently amended) A method of producing a polypeptide according to claim 1[[or 2]], which method comprises culturing a host cell[[s]] ~~as claimed in claim 7~~ under conditions suitable for obtaining expression of the polypeptide and isolating the ~~said~~ polypeptide[[.]], wherein the host cell contains an expression vector comprising a polynucleotide encoding the polypeptide and wherein the expression vector is capable of expressing the polypeptide.

15. (original) A method of identifying a compound having immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity comprising providing a cell capable of expressing the polypeptide of SEQ. ID. No. 2 or a naturally-occurring variant thereof having at least 60% identity over the full length of SEQ ID NO: 2, incubating said cell with a compound under test and monitoring for upregulation of the gene encoding said polypeptide or variant.

16. (original) A polynucleotide capable of expressing *in vivo* an antisense sequence to a coding sequence for the amino acid sequence defined by SEQ. ID. No.2 or a naturally-occurring variant of said coding sequence having at least 60% identity over the full length of said coding sequence for use in therapeutic treatment of a human or non-human animal.

17. (original) An antibody as claimed in claim 8 for use in therapeutic treatment.

18. (original) A set of primers for nucleic acid amplification which target sequences within a cDNA as claimed in claim 4.

19. (currently amended) A nucleic acid probe derived from a polynucleotide as claimed in ~~any one of~~ claim[[s]] 3 [[to 5]].

20. (original) A probe as claimed in claim 19 which is attached to a solid support.

21. (original) A method of predicting responsiveness of a patient to treatment with a Type 1 interferon, which comprises determining the level of the protein defined by the amino acid sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant thereof having at least 60% identity over the full length of SEQ ID NO: 2, or the corresponding mRNA, in a cell sample from said patient, wherein said sample is obtained from said patient following administration of a Type 1 interferon or is treated prior to said determining with a Type 1 interferon *in vitro*.

22. (original) A method as claimed in claim 21 wherein the interferon administered prior to obtaining said sample or used to treat said sample *in vitro* is the interferon proposed for treatment of said patient.

23. (currently amended) A method as claimed in claim 21 ~~or claim 22~~ wherein a sample comprising peripheral blood mononuclear cells isolated from a blood sample of the patient is treated with a Type 1 interferon *in vitro*.

24. (currently amended) A method as claimed in ~~any one of~~ claim[[s]] 21 [[to 23]] wherein said determining comprises determining the level of mRNA encoding the protein defined by the sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant of said protein having at least 60% identity over the full length of SEQ ID NO: 2.

25. (original) A non-human transgenic animal capable of expressing a polypeptide that is claimed in claim 1.

26. (new) A pharmaceutical composition comprising a polynucleotide as claimed in claim 9 and a pharmaceutically acceptable carrier or diluent.

27. (new) A method of treating a patient having a Type 1 interferon treatable disease, which comprises administering to said patient an effective amount of a polynucleotide as claimed in claim 9.